Explore Our History
Established in 2005 through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo has a rich history spanning more than 100 years.
2005
-
2005
Established by joint holding company of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd.
-
2006
Began operations of Daiichi Sankyo Healthcare Co., Ltd.; Daiichi Sankyo, Inc.; and Daiichi Sankyo Europe GmbH
-
2006
Launched Urief®, a drug for dysuria (Daiichi Pharmaceutical Co., Ltd.)
-
2007
Began operations on April 1, 2007 as Daiichi Sankyo Co., Ltd.
-
2008
Acquired U3 Pharma GmbH of Germany and Ranbaxy Laboratories Ltd. of India
-
2009
Launched Prasugrel, an antiplatelet agent and global product, in Germany (as Efient®) and the United States (as Effient®)
2010
-
2010
Launched Rezaltas®, a high-affinity ARB/long-acting calcium antagonist compound
-
2010
Began operations of Daiichi Sankyo Espha Co., Ltd.
-
2010
Launched Inavir®, an anti-influenza virus agent
-
2011
Acquired Plexxikon Inc. of the United States
-
2011
Began operations of Kitasato Daiichi Sankyo Vaccine Co., Ltd.
-
2011
Launched Memary® for treatment of Alzheimer's disease
-
2011
Launched Lixiana®, an oral FXa inhibitor
-
2011
Launched Nexium®, a proton pump inhibitor
-
2011
Consolidated Japan head office and head offices of Japan Group companies into three office buildings in the Nihonbashi area of Tokyo, Japan
-
2011
Established wholly-owned subsidiary Daiichi Sankyo (China) Holdings Co., Ltd.
-
2012
Opened Daiichi Sankyo Kusuri Museum in Tokyo
-
2012
Launched RANMARK®, an antibody that targets RANK ligand
-
2012
Began operations of Japan Vaccine Co., Ltd., a joint venture with GlaxoSmithKline K.K.
-
2012
Launched TENELIA®, a therapeutic agent for type 2 diabetes
-
2013
Launched natural tetrahydrobiopterin agent Biopten® Granules 10%
-
2014
Launched oral antiplatelet agent Efient in Japan
-
2014
Launched CANAGLU® Tablets 100mg for treatment of Type 2 Diabetes Mellitus
-
2014
Received approval in Japan for additional AF and VTE indications for LIXIANA® (edoxaban)
-
2014
Acquired biopharmaceutical company Ambit Biosciences
2015
-
2015
Launched edoxaban, an oral, once-daily anti-coagulant global product, in the United States (as SAVAYSA®) and in Europe (as LIXIANA®)
-
2015
Launched Methylene Blue Injection 50mg, a treatment for methemoglobinemia
-
2015
Launched MOVANTIK®, a treatment for opioid-induced constipation (OIC), in the United States via co-commercialization agreement with AstraZeneca
-
2015
Ranbaxy Laboratories Limited acquired by Sun Pharmaceutical Industries Ltd. via all-stock transition
-
2015
Daiichi Sankyo Healthcare acquired mail-order cosmetics and health food business, Im Co., Ltd.
-
2015
Launched Squarekids® subcutaneous injection syringe, a tetravalent combination vaccine for the prevention of diphtheria, pertussis, tetanus, and poliomyelitis (polio)
-
2016
Launched antiepileptic agent Vimpat®
-
2017
Launched CANALIA® for treatment of type 2 diabetes mellitus in Japan
-
2019
Launched Tarlige® for treatment of pain in Japan.
-
2019
Launched MINNEBRO® for treatment of hypertension in Japan
-
2019
Launched TURALIO™ for treatment of select patients with tenosynovial giant cell tumor
-
2019
Launched FLT3 Inhibitor VANFLYTA® in Japan